CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement

CorMedix shares reached a 52-week low after DaVita's CFO indicated that Medicare add-on payments for the DefenCath catheter lock solution are expected to decline significantly starting in the second quarter of 2027.